Breast Cancer in Argentina: Feasibility for the Implementation of the New TNM Staging System 2018 in A Middle-Income Country

Kress, Roberto Pablo Meiss

doi:10.24218/jcet.2018.20

Cited by 3 publications

(2 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 Hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer is the most common breast cancer subtype in Argentina, affecting 70% of patients. 2 Even though mortality rates from breast cancer have been in decline in Argentina during recent years, the mortality rate is higher in Argentina (17.56 deaths per 100,000 women in 2012) than in most other Latin American countries with the exception of Uruguay (17.78 deaths per 100,000 women in 2012). 3…”

Section: Introductionmentioning

confidence: 99%

Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study

Waller

Mitra

Mycock

et al. 2019

JGO

View full text Add to dashboard Cite

PURPOSE The selective cyclin-dependent kinase 4/6 inhibitor palbociclib was approved in Argentina in 2015 for postmenopausal women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer (ABC) or metastatic breast cancer (MBC) based on phase III study results. The Ibrance Real World Insights (IRIS) study aims to evaluate palbociclib in patients with HR-positive/HER2-negative ABC or MBC in the real-world setting in multiple countries globally. Here we report results from patients enrolled in the IRIS study in Argentina. PATIENTS AND METHODS This retrospective medical chart review study included postmenopausal women with confirmed HR-positive/HER2-negative ABC or MBC who were treated with palbociclib plus letrozole as first-line endocrine-based therapy or with palbociclib plus fulvestrant in women with disease progression after endocrine therapy. Participating physicians reviewed medical records of up to six patients each, collecting demographic and clinical data. Outcomes included progression-free and overall survival rates. RESULTS Records were extracted for 162 patients in Argentina (palbociclib plus letrozole, n = 105 [65%]; palbociclib plus fulvestrant, n = 57 [35%]). The 6-month progression-free survival rate was 94% for patients treated with palbociclib plus letrozole and 95% for patients treated with palbociclib plus fulvestrant; 85% and 80% of patients treated with palbociclib plus letrozole were progression free at 12 and 18 months, respectively. Six-month survival rates were 98% for palbociclib plus letrozole and 98% for palbociclib plus fulvestrant; 93% and 89% of patients treated with palbociclib plus letrozole were alive at 12 and 18 months, respectively. CONCLUSION Results from this first real-world evaluation of clinical outcomes in Argentina suggest that palbociclib plus letrozole or fulvestrant delivers favorable effectiveness, as measured by progression-free and overall survival rates.

show abstract

Section: Introductionmentioning

confidence: 99%

Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study

Waller

Mitra

Mycock

et al. 2019

JGO

View full text Add to dashboard Cite

show abstract

“…Scholars have long emphasised the fragmented nature of the Argentinian health system, which comprises three main subsystems (public, private, and social security) with scarce synergy amongst them. Deficiencies in cancer control have been observed not only in terms of providers and resource management [14–16], but also in terms of the lack of a National Cancer Programme [17, 18], and inequalities in access to diagnosis and treatments [19–21]. The health system in Córdoba is broadly organised as follows: The majority of the working-age population has the social security health insurance system ( Obra Social ), each insurance plan being organised according to the occupation of the beneficiary and are administered by different workers unions.…”

Section: Introductionmentioning

confidence: 99%

Factors influencing oncologists’ prescribing hormonal therapy in women with breast cancer: a qualitative study in Córdoba, Argentina

Eraso

2019

Int J Equity Health

View full text Add to dashboard Cite

Background Hormonal therapy is an integral component for breast cancer treatment in women with oestrogen receptor positive tumours in early-stage and advanced cases of the disease. Little is known about what factors influence oncologists’ prescribing practices, especially non-biological factors, although this information may have important implications for understanding inequalities in health care quality and outcomes. This paper presents findings from research on factors influencing oncologists’ prescribing hormonal therapy for women with early and advanced cases of breast cancer in the city of Córdoba, Argentina. Methods A qualitative study using in-depth, semi-structured interviews with 16 oncologists was conducted. A stratified purposive sampling was used to recruit female and male participants and working at 3 health subsystems (private, social security, public). Data was analysed using the Framework approach. Results According to the respondents, factors influencing prescribing practices of hormonal therapy are varied. Women’s socio-economic status (poverty and wealth) and their level of health literacy can affect oncologists’ prescribing practices. Overall, in comparison to male, female oncologists reported more awareness of patients’ needs, more involvement in communicating drug side-effects, and in offering treatment options in private health settings. The 3 health subsystems provided a differential access to drugs and lines of hormonal treatment, which ranged from a limited availability in the public sector, to administrative restrictions imposed by the social security system, and to a lesser extent, the private sector. This happened in the backdrop of national legislation covering oncological treatments and drugs free of charge. Conclusions Addressing prescribing practices for hormonal therapy as a distinct type of breast cancer treatment (chronic care) is fundamental in the understanding of breast cancer care and can shed light on inequalities in treatments. Identifying the underlying care gaps in the prescription of hormonal therapy can help in the design of tailored interventions. Electronic supplementary material The online version of this article (10.1186/s12939-019-0936-z) contains supplementary material, which is available to authorized users.

show abstract

The hispanic landscape of triple negative breast cancer

Zevallos

Bravo

Bretel

et al. 2020

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Breast Cancer in Argentina: Feasibility for the Implementation of the New TNM Staging System 2018 in A Middle-Income Country

Cited by 3 publications

References 50 publications

Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study

Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study

Factors influencing oncologists’ prescribing hormonal therapy in women with breast cancer: a qualitative study in Córdoba, Argentina

The hispanic landscape of triple negative breast cancer

Contact Info

Product

Resources

About